Synageva BioPharma Release: LAL Deficiency Disease Review Published In Atherosclerosis

LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society. The publication, entitled “Lysosomal Acid Lipase Deficiency–An Under-Recognized Cause of Dyslipidaemia and Liver Dysfunction,” can be accessed at http://dx.doi.org/10.1016/j.atherosclerosis.2014.04.003.

Help employers find you! Check out all the jobs and post your resume.